SCHEMBL843402

SCHEMBL843402

O=Cc1occc1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL5863483 0.77 LMNA (0.35)
SCHEMBL51408 0.72
SCHEMBL19881601 0.72
SCHEMBL8172271 0.70 PTGS2 (0.33)
Water SCHEMBL15210122 0.70 ALDH1A1 (0.41)
SCHEMBL160461 0.70
SCHEMBL4000711 0.70
SCHEMBL1990484 0.70
SCHEMBL1023100 0.70
Water SCHEMBL3454746 0.70 ALDH1A1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107382996-B Specific inhibition plant plasma membrane H+-ATPase compound and preparation method and application thereof 中国农业大学 2020-11-06 CN claimed
US-12583844-B2 Matrix metalloproteinase (MMP) inhibitors and methods of use thereof FORESEE PHARMACEUTICALS USA, INC. (US) 2026-03-24 US disclosed
US-12503460-B2 Matrix metalloproteinase (MMP) inhibitors and methods of use thereof FORESEE PHARMACEUTICALS USA, INC. (US) 2025-12-23 US disclosed
US-12398089-B2 Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand NANJING CHENGZHI CLEAN ENERGY CO. LTD. (CN) 2025-08-26 US disclosed
US-12258335-B1 Matrix metalloproteinase (MMP) inhibitors and methods of use thereof FORESEE PHARMACEUTICALS USA, INC. (US) 2025-03-25 US disclosed
US-20250057957-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2025-02-20 US disclosed
CN-119462623-A Matrix Metalloproteinase (MMP) inhibitors and methods of use thereof 逸达生物科技美国公司 2025-02-18 CN disclosed
CN-119371425-A Nitrogen-containing heterocyclic compound, preparation method and medical application thereof 中国医药研究开发中心有限公司 2025-01-28 CN disclosed
EP-4058437-B9 MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF FORESEE PHARMACEUTICALS USA INC (US) 2025-01-15 EP disclosed
EP-4483875-A2 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2025-01-01 EP disclosed
WO-1995019774-A1 BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY WARNER-LAMBERT COMPANY (US) 1995-07-27 WO disclosed
WO-1994017796-A1 THERAPEUTIC USE OF COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON RXR RETINOID RECEPTORS ALLERGAN, INC. (US) 1994-08-18 WO disclosed
US-4732901-A BRONCHODILATORS BEECHAM GROUP P.L.C. (GB) 1988-03-22 US disclosed
US-4695634-A Hypoglycemic 5-substituted oxazolidine-2,4-diones PFIZER INC. (US) 1987-09-22 US disclosed
US-4622406-A CHEMICAL INTERMEDIATES, TRIMETHYLSILOXY COMPOUNDS PFIZER INC. (US) 1986-11-11 US disclosed
EP-0194093-A2 Substituted heterocyclic acrylic acids and esters, their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1986-09-10 EP disclosed
US-4562267-A Intermediates of hypoglycemic 5-substituted oxazolidine-2,4-diones PFIZER INC. (US) 1985-12-31 US disclosed
US-4423233-A ALPHA-HYDROXY CARBOXIMIDATE INTERMEDIATES PFIZER INC. (US) 1983-12-27 US disclosed
US-4381308-A Hypoglycemic 5-substituted oxazolidine-2,4-diones PFIZER INC. (US) 1983-04-26 US disclosed
US-4332952-A Hypoglycemic 5-substituted oxazolidine-2,4-diones PFIZER INC. (US) 1982-06-01 US disclosed